VERTEX (VX12-809-104) Study

This was a Phase 2 placebo-controlled study of the effects of the combination of lumacaftor and ivacaftor in subjects homozygous or heterozygous for the F508del-CFTR mutation. It is now completed. Please see "Current Studies" for the Phase 3 rollover trial.